Loading...
XETRBNN
Market cap78mUSD
Dec 23, Last price  
3.44EUR
1D
-0.86%
1Q
46.38%
Jan 2017
-79.84%
IPO
-63.44%
Name

BRAIN Biotech AG

Chart & Performance

D1W1MN
XETR:BNN chart
P/E
—
P/S
1.36
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
10.86%
Revenues
55m
+11.77%
7,476,28510,134,51112,987,60821,132,36322,789,95024,105,00027,051,00038,560,00038,225,00038,389,00049,509,00055,335,000
Net income
-8m
L+30.56%
-5,537,256-4,095,361-5,044,485-5,714,554-14,689,820-9,607,000-8,276,000-10,495,000-9,017,000-4,679,000-6,341,000-8,279,000
CFO
-4m
L+184.04%
-5,886,002-4,849,068-3,903,265-4,113,241-8,683,489-5,757,000-5,418,000-3,380,000-4,767,000-3,906,000-1,485,000-4,218,000
Earnings
Feb 26, 2025

Profile

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
URL
https://www.brain-biotech.de/
IPO date
Feb 09, 2016
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
55,335
11.77%
49,509
28.97%
Cost of revenue
62,226
31,229
Unusual Expense (Income)
NOPBT
(6,891)
18,280
NOPBT Margin
36.92%
Operating Taxes
625
176
Tax Rate
0.96%
NOPAT
(7,516)
18,104
Net income
(8,279)
30.56%
(6,341)
35.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
4,659
3,037
Long-term debt
1,441
7,695
Deferred revenue
518
766
Other long-term liabilities
26,158
11,875
Net debt
(763)
351
Cash flow
Cash from operating activities
(4,218)
(1,485)
CAPEX
(2,619)
(6,082)
Cash from investing activities
562
(12,686)
Cash from financing activities
459
(1,966)
FCF
(12,166)
16,201
Balance
Cash
5,407
8,805
Long term investments
1,456
1,576
Excess cash
4,096
7,906
Stockholders' equity
(70,443)
(58,412)
Invested Capital
124,792
114,048
ROIC
15.49%
ROCE
31.02%
EV
Common stock shares outstanding
21,847
21,847
Price
Market cap
EV
EBITDA
(2,237)
22,620
EV/EBITDA
Interest
942
249
Interest/NOPBT
1.36%